INTRODUCTION
MVP
ADVERSE REACTIONS, MVP
This study aimed to evaluate the pregnancy rates, adverse reactions, and medication costs of two luteal phase support regimens: oral dydrogesterone and micronized vaginal progesterone (MVP) pessary in Luteal phase support (LPS) is a medical treatment that involves the intake of progestin, progesterone, human chorionic gonadotropin (HCG), or gonadotrophin-releasing hormone (GnRH) agonists to improve the attainment rate of implantation and pre-embryo life thus supporting and complementing the roles of corpus luteum [A recent Cochrane meta-analysis has reported different methods, prescriptions, and ways of administering LPS in assisted reproductive technologies (ART) [To overcome these potential limitations, Duphaston, a synthetic form of the hormone progesterone known as dydrogesterone, was produced. Duphaston is chemically identical to natural progesterone, but the methyl group in carbon 10 is situated in the alpha position rather than the beta position in natural progesterone [Previous studies have documented the safety, efficacy, and tolerability of DYD [Nevertheless, there are various reports on pregnancy outcomes following the administration of DYD Therefore, it is expected that oral medications with similar outcomes to vaginal medications would be more acceptable to women. The use of oral DYD is as effective as our current standard of care – MVP pessary. Given the pervasive use of MVP and the greater number of 